Clinical trials: sponsored by Stemline Therapeutics, Inc.
Hormone Receptor Positive Malignant Neoplasm of Breast
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
- Trial name
- NCT03088527
- Testing
- RAD140
- Where
- 5 sites in United States
- Volunteers
- 20 people
- Sponsor
- Stemline Therapeutics, Inc.
Metastatic Breast Cancer
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
The purpose of this study is to visualize and quantify ER-binding sites during treatment with Elacestrant (RAD1901)
- Trial name
- NCT02650817
- Testing
- RAD1901
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 16 people
- Sponsor
- Stemline Therapeutics, Inc.
Advanced ER+, HER2-Negative Breast Cancer
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer.
- Trial name
- NCT02338349
- Testing
- Elacestrant
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Stemline Therapeutics, Inc.